• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

验证人 MDR1-MDCK 和 BCRP-MDCK 细胞系以提高对脑穿透的预测。

Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.

机构信息

Medicine Design, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut 06340.

Medicine Design, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut 06340.

出版信息

J Pharm Sci. 2019 Jul;108(7):2476-2483. doi: 10.1016/j.xphs.2019.02.005. Epub 2019 Feb 20.

DOI:10.1016/j.xphs.2019.02.005
PMID:30794795
Abstract

It is of great challenge to predict human brain penetration for substrates of multidrug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), 2 major efflux transporters at blood-brain barrier. Thus, a physiologically based pharmacokinetic (PBPK) model with the incorporation of in vitro MDR1 and BCRP transporter function data and transporter protein expression levels has been developed. As such, it is crucial to generate MDR1 and BCRP substrate data with a high fidelity. In this study, 2 widely used human MDR1 cell lines from Borst and National Institutes of Health laboratories were evaluated using rodent brain penetration data, and the study suggested that the MDR1 expressed in Madin-Darby canine kidney (MDCK) cell line from National Institutes of Health laboratory predicted brain penetration better, particularly for compounds with a high passive permeability. In addition, human BCRP-MDCK cell line with 1 μM PSC833, a specific MDR1 inhibitor, demonstrated the ability to identify BCRP substrates without the confounding of endogenous canine Mdr1. Comparison of human BCRP and mouse Bcrp transporter functions revealed that the functional differences of BCRP between the 2 species is minimal. The incorporation of both the validated MDR1 and BCRP assays into our brain PBPK model has significantly improved the prediction for the brain penetration of MDR1 and BCRP substrates across species.

摘要

预测多药耐药蛋白 1(MDR1)和乳腺癌耐药蛋白(BCRP)这两种主要的血脑屏障外排转运体的人脑中的穿透率极具挑战性。因此,已经开发了一种包含体外 MDR1 和 BCRP 转运体功能数据和转运体蛋白表达水平的基于生理学的药代动力学(PBPK)模型。因此,生成具有高保真度的 MDR1 和 BCRP 底物数据至关重要。在这项研究中,使用啮齿动物脑穿透数据评估了来自 Borst 和美国国立卫生研究院实验室的 2 种广泛使用的人 MDR1 细胞系,研究表明,美国国立卫生研究院实验室的 Madin-Darby 犬肾(MDCK)细胞系中表达的 MDR1 更好地预测了脑穿透,尤其是对于具有高被动渗透性的化合物。此外,用 1 μMPSC833(一种特定的 MDR1 抑制剂)处理的人 BCRP-MDCK 细胞系具有识别 BCRP 底物的能力,而不会受到内源性犬 Mdr1 的干扰。人 BCRP 和小鼠 Bcrp 转运体功能的比较表明,这 2 个物种之间 BCRP 的功能差异很小。将经过验证的 MDR1 和 BCRP 测定法纳入我们的大脑 PBPK 模型中,大大提高了对跨物种 MDR1 和 BCRP 底物脑穿透的预测能力。

相似文献

1
Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.验证人 MDR1-MDCK 和 BCRP-MDCK 细胞系以提高对脑穿透的预测。
J Pharm Sci. 2019 Jul;108(7):2476-2483. doi: 10.1016/j.xphs.2019.02.005. Epub 2019 Feb 20.
2
Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.犬 P-糖蛋白缺陷型 MDCK II 细胞系的特征鉴定和验证及其在外排底物筛选中的应用。
Pharm Res. 2020 Sep 11;37(10):194. doi: 10.1007/s11095-020-02895-9.
3
Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.利用双人类转运体MDCKII-MDR1-BCRP细胞系评估血脑屏障处的外排作用。
Drug Metab Dispos. 2024 Jan 9;52(2):95-105. doi: 10.1124/dmd.123.001476.
4
Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.研究 MDR1 过表达细胞系,以利用体外外排活性为脑分布推导定量预测方法。
Eur J Pharm Sci. 2020 Jan 15;142:105119. doi: 10.1016/j.ejps.2019.105119. Epub 2019 Nov 1.
5
Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1.拓展体外外排测定工具盒:经 CRISPR-Cas9 编辑的、人源 BCRP 表达完全而缺乏犬源 MDR1 的 MDCK 细胞系
J Pharm Sci. 2021 Jan;110(1):388-396. doi: 10.1016/j.xphs.2020.09.039. Epub 2020 Sep 29.
6
In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.体外评估多巴胺 β-羟化酶抑制剂与人 P-糖蛋白和乳腺癌耐药蛋白的相互作用。
Eur J Pharm Sci. 2018 May 30;117:35-40. doi: 10.1016/j.ejps.2018.02.006. Epub 2018 Feb 8.
7
Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.通过质谱法定量 ABC 转运体及其对利伐沙班经转运体介导的药物相互作用的体外至体内预测的影响。
Eur J Pharm Biopharm. 2020 Mar;148:27-37. doi: 10.1016/j.ejpb.2020.01.002. Epub 2020 Jan 13.
8
Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting.利用临床前数据作为预测人类脑组织靶向的工具。
ACS Chem Neurosci. 2021 Mar 17;12(6):1007-1017. doi: 10.1021/acschemneuro.0c00807. Epub 2021 Mar 2.
9
Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.运用体外转运体研究和动物模型预测 P-糖蛋白和乳腺癌耐药蛋白底物的人脑渗透。
J Pharm Sci. 2018 Aug;107(8):2225-2235. doi: 10.1016/j.xphs.2018.03.018. Epub 2018 Mar 30.
10
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.吉美替尼(7-叔丁氧基亚氨基甲基喜树碱)通过乳腺癌耐药蛋白、P-糖蛋白和多药耐药蛋白2的体外转运
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3307-13. doi: 10.1158/1535-7163.MCT-07-0461.

引用本文的文献

1
Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations.齐德替尼对多种ROS1耐药突变的选择性靶向作用。
Mol Cancer Ther. 2025 Jul 2;24(7):1005-1019. doi: 10.1158/1535-7163.MCT-25-0025.
2
Considerations in K-based Strategy for Selecting CNS-targeted Drug Candidates with Sufficient Target Coverage and Substantial Pharmacodynamic Effect.基于K值策略选择具有足够靶点覆盖和显著药效学效应的中枢神经系统靶向候选药物的考量因素。
AAPS J. 2025 Feb 28;27(2):52. doi: 10.1208/s12248-025-01035-8.
3
Molecular mechanism of type ib MET inhibitors and their potential for CNS tumors.
ib型MET抑制剂的分子机制及其在中枢神经系统肿瘤中的应用潜力
Sci Rep. 2025 Feb 26;15(1):6926. doi: 10.1038/s41598-025-85631-w.
4
Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly?用于体内P-糖蛋白底物脑细胞外液药代动力学机制预测的体外数据的可靠性;我们的缩放是否正确?
J Pharmacokinet Pharmacodyn. 2025 Feb 8;52(2):16. doi: 10.1007/s10928-025-09963-w.
5
Is there a possibility that P-glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?P-糖蛋白是否有可能降低雄性生殖毒性,而乳腺癌耐药蛋白却没有这种作用?
Clin Transl Sci. 2024 Oct;17(10):e70027. doi: 10.1111/cts.70027.
6
ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.三磷酸腺苷结合盒转运蛋白抑制剂的效力和底物药物亲和力是成功提高药物向大脑递送至关键决定因素。
Fluids Barriers CNS. 2024 Aug 5;21(1):62. doi: 10.1186/s12987-024-00562-4.
7
Applicability of MDR1 Overexpressing Abcb1KO-MDCKII Cell Lines for Investigating In Vitro Species Differences and Brain Penetration Prediction.过表达MDR1的Abcb1基因敲除MDCKII细胞系在研究体外种属差异和脑穿透预测中的适用性
Pharmaceutics. 2024 May 29;16(6):736. doi: 10.3390/pharmaceutics16060736.
8
Natural polymers as potential P-glycoprotein inhibitors: Pre-ADMET profile and computational analysis as a proof of concept to fight multidrug resistance in cancer.天然聚合物作为潜在的P-糖蛋白抑制剂:ADMET前概况及计算分析作为对抗癌症多药耐药性概念验证
Heliyon. 2023 Aug 24;9(9):e19454. doi: 10.1016/j.heliyon.2023.e19454. eCollection 2023 Sep.
9
Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.DZD1516 的临床前和临床活性,DZD1516 是一种全血脑屏障穿透的、高选择性 HER2 抑制剂。
Breast Cancer Res. 2023 Jul 6;25(1):81. doi: 10.1186/s13058-023-01679-4.
10
Interlaboratory Variability in the Madin-Darby Canine Kidney Cell Proteome.马迪-达比犬肾细胞蛋白质组的实验室间变异性。
Mol Pharm. 2023 Jul 3;20(7):3505-3518. doi: 10.1021/acs.molpharmaceut.3c00108. Epub 2023 Jun 7.